Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

Thumbnail

Outcome Health execs convicted in $1B fraud scheme

Three former executives from Outcome Health, a health technology startup company based in Chicago, have been convicted by a jury in a fraud scheme amounting to approximately $1 billion.

Thumbnail

DOJ to appeal abortion pill case to Supreme Court

“The Justice Department strongly disagrees with the Fifth Circuit’s decision in Alliance for Hippocratic Medicine v. FDA to deny in part our request for a stay pending appeal,” Attorney General Merrick Garland said April 13.

Thumbnail

Political climate leads to loss of labor and delivery services

Bonner General Health, based in Sandpoint, Idaho, alerted the public about the upcoming discontinuation of labor and delivery services.

SCAI blasts Medicare payment cuts to cardiology, asks members to take action

The group hopes its members can increase congressional support of a new bill introduced in the House. 

Thumbnail

Sanofi’s $2.9B acquisition of Provention Bio delayed by FTC review

According to Sanofi, it has withdrawn and refiled its premerger notification and report form with the FTC to give the agency more time to review the deal.

cardiovascular risk infectious disease hospitalization

CMS proposes 2.8% rate increase for inpatient payments in 2024

CMS is also proposing that rural emergency hospitals be designated graduate medical education training sites, enabling more medical students to train in those areas.

Thumbnail

Drugmakers condemn judge’s suspension of abortion pill access

The uncertainty the ruling creates could have a big impact on the pharmaceutical industry for years to come. 

Thumbnail

Abortion pill legality in question after conflicting federal judgments

The use of a common medication used to end pregnancy is now in question after a federal judge in Texas struck down its legality in a shocking decision.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.